Drug Search Results
More Filters [+]

HRS-1167

Alternative Names: HRS-1167, HRS 1167, HRS1167
Latest Update: 2024-06-03
Latest Update Note: News Article

Product Description

HRS-1167 is a drug candidate from Jiangsu HengRui Medicine for the treatment of Advanced Solid Tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05473624?term=HRS-1167&draw=2&rank=1)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hengrui Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HRS-1167

Countries in Clinic: China, Germany, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Ovarian Cancer

Phase 1: Healthy Volunteers|Oncology Solid Tumor Unspecified|Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DDRiver 501

P1

Not yet recruiting

Prostate Cancer|Ovarian Cancer

2026-03-09

39%

HRS-1167-201-Bev

P2

Recruiting

Ovarian Cancer

2025-10-01

49%

HRS-1167-I-101

P1

Recruiting

Oncology Solid Tumor Unspecified

2024-12-31

39%

HRS-1167-102

P1

Completed

Oncology Solid Tumor Unspecified|Healthy Volunteers

2024-02-05

28%

Recent News Events